| (210) | Number of the EPO application | 20739523 |
| (220) | Filing date of the EPO application | 2020.06.19 |
| (80) | EPO patent specification publication (B) | EPB nr. 45/2023, 2023.11.08 |
| (110) | EPO patent number | 3989972 |
| (11) | Number of the document | MD 3989972 T2 |
| (21) | Number of the application | e 2022 0509 |
| (71) | Name(s) of applicant(s), code of the country | ELI LILLY AND COMPANY, US; |
| (72) | Name(s) of inventor(s), code of the country | COATES David Andrew, US;
FIELDS Todd, US;
HO Joseph Daniel, US;
QU Fucheng, US; |
| (73) | Name(s) of owner(s), code of the country | ELI LILLY AND COMPANY, US; |
| (54) | Title of the invention | Glucagon-like peptide 1 receptor agonists |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | A61K 31/4439 (2006.01.01); C07D 405/14 (2006.01.01); A61P 3/10 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2022.05.31 |
| (49) | Date of publication of the translation of the validated European patent specification | 2024.05.31 |
| (30) | Priority | 201962868117 P, 2019.06.28, US; 201962904906 P, 2019.09.24, US |
| (74) | Patent attorney | (Procedură) PARASCA Dumitru, str. Eminescu nr. 40, ap. 13, c/p 28, MD-2012, Chişinău, Republica Moldova |
| (86) | International application | PCT/US2020/038617, 2020.06.19 |
| (87) | International publication | WO 2020/263695, 2020.12.30 |